INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
June 23, 2023 16:10 ET
|
Inovio Pharmaceuticals, Inc.
Plymouth Meeting, Pa., June 23, 2023 (GLOBE NEWSWIRE) -- INOVIO (NASDAQ:INO) has released the following pursuant to an order of the UNITED STATES DISTRICT COURT EASTERN DISTRICT OF...
Inovio Announces Initiation of “MD Anderson’s HPV-Related Cancers Moon Shot” Phase 2 Trial in New HPV Indications
December 04, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
Phase 2 cancer study will evaluate T cell-activating immunotherapy MEDI0457 with MedImmune’s durvalumab targeting several HPV-related cancers PLYMOUTH MEETING, Pa., Dec. 04, 2018 (GLOBE NEWSWIRE)...
Inovio, DNA 암호화 단일클론 항체(dMAb™) 플랫폼의 효능 입증하는 임상전 논문 3건과 2019년 첫 임상시험 계획 발표
November 26, 2018 21:35 ET
|
Inovio Pharmaceuticals, Inc.
미국 펜실베이니아주 플리머스미팅, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc.(NASDAQ: INO)가 최신 논문 3건을 통해 DNA 암호화 단일클론 항체(dMAb™) 기술이 임상 전 모델의 심혈관 질환 치료 및 에볼라 바이러스와 라임병 원인 박테리아의 감염 예방에 인상적인 효과를...
Inovio在三項臨床前試驗結果文獻中進一步顯示Inovio的DNA編碼單克隆抗體（dMAb™）平台的療效，並準備在2019年初進行首次臨床試驗
November 26, 2018 21:35 ET
|
Inovio Pharmaceuticals, Inc.
賓夕法尼亞州普利茅斯會議, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc。（NASDAQ: INO）今日宣佈該公司最近發表的三項DNA編碼單克隆抗體（dMAb™）技術研究結果令人印象深刻。...
イノビオ社、3件の前臨床試験で同社のDNAコード化モノクローナル抗体 (dMAb™) プラットフォームの効力をさらに実証し、2019年初旬の初回臨床試験に向けて準備を進める
November 26, 2018 21:35 ET
|
Inovio Pharmaceuticals, Inc.
ペンシルベニア州プリマス･ミーティング , Nov. 27, 2018 (GLOBE NEWSWIRE) -- イノビオ･ファーマシューティカルズ (Inovio Pharmaceuticals, Inc.、NASDAQ: INO) は本日、DNAコード化モノクローナル抗体 (dMAb™)...
Inovio Further Demonstrates Potency of its DNA-Encoded Monoclonal Antibody (dMAb™) Platform in Three Preclinical Publications and Prepares for First Clinical Trial in Early 2019
November 26, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that three recent published studies of its DNA-Encoded monoclonal antibody (dMAb™)...
Inovio Prepares for Growth & Commercialization With Leadership Appointments
November 15, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
Prominent immunologist joins Scientific Advisory BoardR&D leader appointed Chief Scientific OfficerIndustry veteran appointed Vice President, Commercial PLYMOUTH MEETING, Pa., Nov. 15, 2018 ...
Inovio Pharmaceuticals Reports 2018 Third Quarter Financial Results
November 08, 2018 16:05 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a late-stage biotechnology company focused on the development and commercialization of DNA...
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
November 05, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that the Company will participate in the following upcoming investment...
Inovio의 HIV 백신 PENNVAX®-GP, 피내 투여 시 강력하고 지속적인 항체, T세포 면역 반응 나타내
October 26, 2018 02:28 ET
|
Inovio Pharmaceuticals, Inc.
미국 펜실베이니아주 플리머스미팅, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (나스닥: INO)는 자사의 합성백신인 PENNVAX®-GP가 임상1상 연구 결과 피내 투여 시 지속적이고 강력한 항체와 T세포 면역 반응을 일으키는 것으로 나타났다고 밝혔다. 본 연구에서는 신체 건강한...